Skip to main content

Table 1 Bioluminescence intensity levels emitted in different body sections of mice along the experimental time

From: An Auristatin nanoconjugate targeting CXCR4+ leukemic cells blocks acute myeloid leukemia dissemination

  Day after i.v. injection of cells
Treatment1468111213
Full bodyVEH6.61E+057.91E+051.29E+063.76E+062.95E+074.37E+076.44E+07
T22-AUR6.33E+058.43E+051.25E+061.65E+061.22E+071.92E+072.96E+07
 p value0.46240.56750.39040.00020.00030.00020.0002
Hindlimbs section (bone marrow)VEH2.03E+052.80E+054.94E+051.57E+061.54E+072.21E+072.93E+07
T22-AUR1.95E+053.01E+054.67E+057.20E+058.34E+061.25E+071.80E+07
 p value0.43750.43770.17770.00020.00430.00090.0033
Abdominal section (extramedullar)VEH1.94E+052.51E+054.76E+051.51E+069.13E+061.52E+072.70E+07
T22-AUR1.77E+052.88E+054.44E+055.39E+051.41E+062.45E+064.70E+06
 p value0.26990.16510.54010.00020.00020.00020.0002
  1. Levels of luminescence detected using the IVIS Spectrum in mice treated with vehicle (VEH) or T22-GFP-H6-Auristatin in full body, hindlimbs section (bone marrow), and in abdominal section (including liver and spleen) of mice during the experiment. Results are presented by mean total flux [photons/second] of radiance detected in mice for each group. U of Mann-Whitney test was used to assess the significance of the differences between groups. These differences were considered statistically significant when the p value was lower than 0.05 (bold values)
  2. BLI bioluminescence, i.v. intravenously, T22-AUR T22-GFP-H6-Auristatin group, VEH vehicle group